Gilead Sciences (GILD) Misses Q1 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Gilead Sciences (GILD) PT Lowered to $118 at UBS
April 29, 2016 8:27 AM EDTUBS analyst Marc Goodman lowered his price target on Gilead Sciences (NASDAQ: GILD) to $118.00 (from $130.00) following Q1 results but maintained a Buy rating.
Goddman commented, "We have lowered our HCV sales estimates to reflect lower ASPs (higher rebates to defend share from Merck's... More
Gilead Sciences (GILD) Needs M&A to Fill the Gap Following HCV Miss - BMO Capital
April 29, 2016 7:40 AM EDTBMO Capital analyst M. Ian Somaiya lowered his price target on Gilead Sciences (NASDAQ: GILD) to $97.00 (from $102.00) following the HCV miss. The firm maintained a Market Perform rating, saying it increases the need for pipeline.
Somaiya commented, "Gilead reported 1Q16 EPS... More
Baird Maintains Bullish View on Gilead Sciences (GILD) Despite Top-Line Miss on U.S. Hep C Sales
April 29, 2016 7:30 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and $135 on Gilead Sciences (NASDAQ: GILD) despite a top-line miss driven by weaker U.S. Hep C sales.
Skorney commented, "U.S. Hep C sales came in several hundred million dollars short of expectations.... More
Maxim Group Downgrades Gilead Sciences (GILD) to Hold
April 29, 2016 7:06 AM EDTMaxim Group downgraded Gilead Sciences (NASDAQ: GILD) from Buy to Hold.
Analyst Jason Kolbert highlighted:
Gilead reported quarterly results with total top-line revenues of $7.6B missing consensus of $7.7B by a hair. Non-GAAP quarterly net income was $4.3B or $3.03 per diluted share. The company ended the period with $21.3B in cash and $22B in debt.HCV revenues continue to drive Gilead but tough comps, the laws of growth (for big numbers), and... MoreGilead Sciences (GILD) PT Trimmed to $123 at Leerink Partners
April 29, 2016 6:50 AM EDTLeerink Partners analyst Geoffrey Porges trimmed his price target on Gilead Sciences (NASDAQ: GILD) to $123.00 (from $127.00) following disappointing Q1 results but maintained an Outperform rating.
Porges commented, "The weakness came in the HCV products, where revenue slid in the US market in the face of... More
